Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6593908 | 0.78 | TSHR (0.46) | ESR2GPR35CASP6TSHRL3MBTL1 | |
| SCHEMBL27873028 | 0.78 | ESR2 (0.41) | ESR2GPR35CASP6TSHRLMNA | |
| SCHEMBL28259792 | 0.76 | GPR35 (0.41) | ESR2GPR35TSHRGSK3BL3MBTL1 | |
| SCHEMBL4584130 | 0.73 | GSK3B (0.59) | GPR35TSHRGSK3BL3MBTL1TDP1 | |
| SCHEMBL16737138 | 0.73 | IDO1 (0.40) | LMNAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL27894129 | 0.71 | ALDH1A1 (0.47) | ESR2LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL4159524 | 0.70 | CASP6 (0.42) | ESR2GPR35CASP6TSHRGSK3B | |
| SCHEMBL1847303 | 0.69 | ESR2 (0.58) | ESR2CASP6TSHRLMNAL3MBTL1 | |
| SCHEMBL27911282 | 0.68 | ALDH1A1 (0.42) | ESR2LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL8841185 | 0.68 | CASP6 (0.62) | CASP6TSHRLMNATDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118530294-B | Aryl diamine immobilized linker, precursor thereof, preparation method and application | 浙江大学 | 2025-02-14 | — | — | CN | disclosed |
| US-9834537-B2 | Compounds as chloride channel blocking agent | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2017-12-05 | — | — | US | disclosed |
| CN-103402994-B | As the heteroaryl derivative of the NACHR conditioning agents of α 7 | 鲁宾有限公司 | 2017-05-31 | — | — | CN | disclosed |
| US-20150148550-A1 | NOVEL COMPOUNDS AS CHLORIDE CHANNEL BLOCKING AGENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148550-A1 | NOVEL COMPOUNDS AS CHLORIDE CHANNEL BLOCKING AGENT | CACNB2, CACNB1, CACNB4 | ESR2 3444/4885GPR35 1062/4885CASP6 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.